7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Inflammation D007249 119 associated lipids
Insulin Resistance D007333 99 associated lipids
Jaw Diseases D007571 4 associated lipids
Jaw, Edentulous D007575 1 associated lipids
Jaw, Edentulous, Partially D007576 1 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Labyrinthitis D007762 2 associated lipids
Legg-Calve-Perthes Disease D007873 1 associated lipids
Leukemia D007938 74 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Lung Neoplasms D008175 171 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lymphatic Metastasis D008207 10 associated lipids
Lymphocytosis D008218 2 associated lipids
Macular Degeneration D008268 5 associated lipids
Malocclusion D008310 3 associated lipids
Malocclusion, Angle Class I D008311 1 associated lipids
Mandibular Diseases D008336 5 associated lipids
Mandibular Injuries D008338 1 associated lipids
Measles D008457 3 associated lipids
Mitral Valve Insufficiency D008944 4 associated lipids
Mitral Valve Stenosis D008946 3 associated lipids
Fluorosis, Dental D009050 1 associated lipids
Mucocutaneous Lymph Node Syndrome D009080 9 associated lipids
Multiple Myeloma D009101 13 associated lipids
Musculoskeletal Diseases D009140 2 associated lipids
Cardiomyopathies D009202 10 associated lipids
Myocardial Infarction D009203 21 associated lipids
Neoplasm Invasiveness D009361 23 associated lipids
Neoplasms, Experimental D009374 10 associated lipids
Neoplastic Syndromes, Hereditary D009386 1 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Nerve Degeneration D009410 53 associated lipids
Neuroblastoma D009447 66 associated lipids
Obesity D009765 29 associated lipids
Obesity, Morbid D009767 8 associated lipids
Ossification, Heterotopic D009999 2 associated lipids
Osteitis D010000 10 associated lipids
Osteitis Deformans D010001 3 associated lipids
Osteoarthritis D010003 4 associated lipids
Osteolysis D010014 8 associated lipids
Osteolysis, Essential D010015 1 associated lipids
Osteonecrosis D010020 5 associated lipids
Osteopetrosis D010022 1 associated lipids
Osteoporosis D010024 12 associated lipids
Osteosclerosis D010026 2 associated lipids
Otosclerosis D010040 2 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Respirovirus Infections D010253 3 associated lipids
Paraneoplastic Syndromes D010257 4 associated lipids
Periapical Diseases D010483 4 associated lipids
Periapical Granuloma D010484 3 associated lipids
Periapical Periodontitis D010485 6 associated lipids
Pericardial Effusion D010490 2 associated lipids
Familial Mediterranean Fever D010505 12 associated lipids
Periodontal Diseases D010510 15 associated lipids
Periodontal Pocket D010514 9 associated lipids
Periodontitis D010518 22 associated lipids
Aggressive Periodontitis D010520 8 associated lipids
Periostitis D010522 1 associated lipids
Polycystic Ovary Syndrome D011085 14 associated lipids
Polycythemia Vera D011087 13 associated lipids
Prediabetic State D011236 1 associated lipids
Pregnancy Complications, Hematologic D011250 11 associated lipids
Prenatal Exposure Delayed Effects D011297 2 associated lipids
Progeria D011371 3 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Prosthesis Failure D011475 1 associated lipids
Radicular Cyst D011842 2 associated lipids
Rheumatic Fever D012213 1 associated lipids
Rheumatic Diseases D012216 7 associated lipids
Root Resorption D012391 2 associated lipids
Rupture, Spontaneous D012422 1 associated lipids
Sarcoma, Ewing D012512 2 associated lipids
Osteosarcoma D012516 50 associated lipids
Scleroderma, Systemic D012595 16 associated lipids
Sclerosis D012598 5 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Stomatitis D013280 14 associated lipids
Synovitis D013585 15 associated lipids
Synovitis, Pigmented Villonodular D013586 1 associated lipids
Takayasu Arteritis D013625 3 associated lipids
Temporomandibular Joint Disorders D013705 4 associated lipids
Thinness D013851 11 associated lipids
Thyroid Diseases D013959 8 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Tinnitus D014012 4 associated lipids
Tooth Migration D014085 2 associated lipids
Tooth Mobility D014086 2 associated lipids
Tooth Resorption D014091 1 associated lipids
Uremia D014511 33 associated lipids
Urologic Neoplasms D014571 2 associated lipids
Vascular Diseases D014652 16 associated lipids
Vision Disorders D014786 10 associated lipids
Vitamin D Deficiency D014808 13 associated lipids
Wounds and Injuries D014947 20 associated lipids
Osteoarthritis, Hip D015207 4 associated lipids
Weight Gain D015430 101 associated lipids
Weight Loss D015431 56 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Schinke T et al. Molecular determinants of arterial calcification. 1998 Ann. Med. pmid:9920355
Akatsu T et al. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. 1998 Bone pmid:9855457
Murakami T et al. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. 1998 Biochem. Biophys. Res. Commun. pmid:9837778
Yun TJ et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. 1998 J. Immunol. pmid:9834095
Vidal NO et al. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. 1998 J. Endocrinol. pmid:9795357
Horwood NJ et al. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. 1998 Endocrinology pmid:9794488
Hakeda Y et al. Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts. 1998 Biochem. Biophys. Res. Commun. pmid:9790989
Hofbauer LC et al. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. 1998 Biochem. Biophys. Res. Commun. pmid:9784422
Filvaroff E and Derynck R Bone remodelling: a signalling system for osteoclast regulation. 1998 Curr. Biol. pmid:9768352
Takai H et al. Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. 1998 J. Biol. Chem. pmid:9765225
Akatsu T et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. 1998 Biochem. Biophys. Res. Commun. pmid:9753612
Hofbauer LC and Heufelder AE Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. 1998 Eur. J. Endocrinol. pmid:9724069
Yamamoto M et al. Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. 1998 Endocrinology pmid:9724059
Mizuno A et al. Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. 1998 Gene pmid:9714833
Vidal ON et al. Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. 1998 Biochem. Biophys. Res. Commun. pmid:9703989
Brändström H et al. Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. 1998 Biochem. Biophys. Res. Commun. pmid:9703945
Morinaga T et al. Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor. 1998 Eur. J. Biochem. pmid:9688283
Kwon BS et al. TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. 1998 FASEB J. pmid:9657524
Tsuda E and Higashio K [Osteoclastogenesis inhibitory factor (OCIF)/OPG]. 1998 Nippon Rinsho pmid:9648461
Mizuno A et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. 1998 Biochem. Biophys. Res. Commun. pmid:9647741
Brändström H et al. Regulation of osteoprotegerin mRNA levels by prostaglandin E2 in human bone marrow stroma cells. 1998 Biochem. Biophys. Res. Commun. pmid:9642127
Tsukii K et al. Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. 1998 Biochem. Biophys. Res. Commun. pmid:9610359
Emery JG et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. 1998 J. Biol. Chem. pmid:9603945
Matsuzaki K et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. 1998 Biochem. Biophys. Res. Commun. pmid:9600092
Bucay N et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. 1998 Genes Dev. pmid:9573043
Tomoyasu A et al. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. 1998 Biochem. Biophys. Res. Commun. pmid:9571159
Lacey DL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. 1998 Cell pmid:9568710
Yasuda H et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. 1998 Proc. Natl. Acad. Sci. U.S.A. pmid:9520411
Yasuda H et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. 1998 Endocrinology pmid:9492069
Yamaguchi K et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. 1998 J. Biol. Chem. pmid:9478964
Miyamoto A et al. Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. 1998 Biochem. Biophys. Res. Commun. pmid:9464281
Hofbauer LC and Heufelder AE Osteoprotegerin: a novel local player in bone metabolism. 1997 Eur. J. Endocrinol. pmid:9368500
Simonet WS et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. 1997 Cell pmid:9108485
pmid:29502401
Li N et al. Calycosin attenuates osteoporosis and regulates the expression of OPG/RANKL in ovariectomized rats MAPK signaling. 2016 Pharmazie pmid:29441931
pmid:29402836
pmid:29348072
pmid:29313442
pmid:29262817
pmid:29253005
pmid:29121799
pmid:29050490
pmid:29025654
pmid:28957555
Ozaki Y et al. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. 2017 PLoS ONE pmid:28937990
Tschiderer L et al. Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. 2017 PLoS ONE pmid:28837646
Choi EM et al. Actein alleviates 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated cellular dysfunction in osteoblastic MC3T3-E1 cells. 2017 Environ. Toxicol. pmid:28836330
pmid:28814613
pmid:28805201
pmid:28774557
pmid:28772237
pmid:28758134
pmid:28742795
pmid:28739719
Chen X et al. Emodin suppresses cadmium-induced osteoporosis by inhibiting osteoclast formation. 2017 Environ. Toxicol. Pharmacol. pmid:28738286
Åšliwicka E et al. Serum irisin and myostatin levels after 2 weeks of high-altitude climbing. 2017 PLoS ONE pmid:28732027
pmid:28731198
pmid:28721974
pmid:28700003
pmid:28683789
pmid:28674791
pmid:28674790
pmid:28661441
pmid:28654984
pmid:28618255
pmid:28617323
pmid:28614819
Bergdolt S et al. Osteoblast-specific overexpression of complement receptor C5aR1 impairs fracture healing. 2017 PLoS ONE pmid:28614388
pmid:28605877
pmid:28593808
pmid:28577080
pmid:28576140
pmid:28567553
pmid:28556971
Middleton K et al. Microfluidic co-culture platform for investigating osteocyte-osteoclast signalling during fluid shear stress mechanostimulation. 2017 J Biomech pmid:28552413
pmid:28530511
pmid:28494644
Spirlandeli AL et al. Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment. 2017 Clinics (Sao Paulo) pmid:28492723
pmid:28488158
pmid:28473060
pmid:28450653
pmid:28429221
pmid:28421466
pmid:28386999
pmid:28385082
pmid:28373003
pmid:28367895
pmid:28363435
pmid:28337794
pmid:28320782
Liu J et al. MicroRNA-32 promotes calcification in vascular smooth muscle cells: Implications as a novel marker for coronary artery calcification. 2017 PLoS ONE pmid:28319142
pmid:28318623
pmid:28303296
pmid:28302565
pmid:28290259
pmid:28285639
pmid:28263839
Songia P et al. Identification of Patients Affected by Mitral Valve Prolapse with Severe Regurgitation: A Multivariable Regression Model. 2017 Oxid Med Cell Longev pmid:28261377
pmid:28260080
Jia J et al. Estrogen stimulates osteoprotegerin expression via the suppression of miR-145 expression in MG-63 cells. 2017 Mol Med Rep pmid:28260003

Table of Content